Candel Therapeutics Inc (CADL): Next-Year EPS Estimate 25.46%
As of 2026-08-13, Candel Therapeutics Inc (CADL) has a next-year EPS growth estimate of 25.46%. Featured in our EPS revision report on 2026-06-30.
On 2026-08-12, analyst consensus for CADL's next-year EPS growth shifted from 25.52% to 25.46% — a negative change of 0.06 percentage points. The revised estimate has been sustained across 2 subsequent trading sessions. Current-year growth is projected at -29.33%.
What's Driving This
Contrary to the premise of an upgrade, the only EPS revision in the data is a downgrade: on 2026-07-13 analysts lowered the next-year EPS growth estimate from 38.14% to 25.52%, now 25.46%. The clinical headline—extended clinical benefit across multiple endpoints from the Phase 3 CAN-2409 trial in localized prostate cancer at AUA 2026—may support sentiment but is not tied to any earnings beat, guidance raise, or contract win. No headline explains an upward estimate revision, and the data show
Generated 2026-10-29 from news as of 2026-08-13
Current Snapshot
- Sector
- Healthcare
- Industry
- Biotechnology
- EPS growth next year
- 25.46%
- EPS growth this year
- -29.33%
- EPS next quarter (est)
- -$0.25
- Last price
- $11.26
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-08-13 | 25.46% | -29.33% | -$0.25 | $11.26 |
| 2026-08-12 | 25.46% | -29.33% | -$0.23 | $10.68 |
| 2026-08-11 | 25.52% | -29.33% | -$0.23 | $10.65 |
| 2026-08-10 | 25.52% | -29.33% | -$0.23 | $10.50 |
| 2026-08-09 | 25.52% | -29.33% | -$0.23 | $10.59 |
| 2026-08-07 | 25.52% | -29.33% | -$0.23 | $10.59 |
| 2026-08-06 | 25.52% | -29.33% | -$0.23 | $10.58 |
| 2026-08-05 | 25.52% | -29.33% | -$0.23 | $10.46 |
| 2026-08-04 | 25.52% | -29.33% | -$0.23 | $10.51 |
| 2026-08-03 | 25.52% | -29.33% | -$0.23 | $10.07 |
| 2026-08-02 | 25.52% | -29.33% | -$0.23 | $10.01 |
| 2026-07-31 | 25.52% | -29.33% | -$0.23 | $10.01 |
| 2026-07-30 | 25.52% | -29.33% | -$0.23 | $9.87 |
| 2026-07-29 | 25.52% | -29.33% | -$0.23 | $9.40 |
| 2026-07-28 | 25.52% | -29.33% | -$0.23 | $9.68 |
| 2026-07-27 | 25.52% | -29.33% | -$0.23 | $9.96 |
| 2026-07-26 | 25.52% | -29.33% | -$0.23 | $9.56 |
| 2026-07-24 | 25.52% | -29.33% | -$0.23 | $9.56 |
| 2026-07-23 | 25.52% | -29.33% | -$0.23 | $9.86 |
| 2026-07-22 | 25.52% | -29.33% | -$0.23 | $10.09 |
| 2026-07-21 | 25.52% | -29.33% | -$0.23 | $10.22 |
| 2026-07-20 | 25.52% | -29.33% | -$0.23 | $9.57 |
| 2026-07-19 | 25.52% | -29.33% | -$0.23 | $10.18 |
| 2026-07-17 | 25.52% | -29.33% | -$0.23 | $10.18 |
| 2026-07-16 | 25.52% | -29.33% | -$0.23 | $9.48 |
| 2026-07-15 | 25.52% | -29.33% | -$0.23 | $9.64 |
| 2026-07-14 | 25.52% | -29.33% | -$0.23 | $9.87 |
| 2026-07-13 | 25.52% | -29.33% | -$0.23 | $9.64 |
| 2026-07-12 | 38.14% | -28.17% | -$0.23 | $9.49 |
| 2026-07-09 | 38.14% | -28.17% | -$0.23 | $9.89 |
Reports Featuring CADL
Recent News
- Candel Therapeutics Reports Extended Clinical Benefit Over Multiple Clinical Endpoints in Patients from Phase 3 Trial of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer Under Prolonged Follow-up at AUA 2026 Annual MeetingGlobeNewswire
- Candel Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate HighlightsGlobeNewswire
Screen Performance
Aggregate stats across all 2145 tickers our top-EPS-revision screen has flagged over the past 225 days.
- Median return since detection
- -2.9%
- % of tickers in the green
- 43%
- Median return on winners
- +22.8%
- Large revisions captured
- 2246
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Also Tracked by Our Screen
Frequently Asked Questions
What is Candel Therapeutics Inc's next-year EPS growth estimate?▾
As of 2026-08-13, Candel Therapeutics Inc (CADL) has a next-year EPS growth estimate of 25.46%, based on analyst consensus.
When was the latest EPS estimate revision for CADL?▾
The most recent revision occurred on 2026-08-12, when analysts adjusted the next-year EPS growth estimate from 25.52% to 25.46%.
What sector and industry does Candel Therapeutics Inc belong to?▾
Candel Therapeutics Inc operates in the Healthcare sector, specifically the Biotechnology industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. CADL appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. Candel Therapeutics Inc (CADL) appears here because it was detected by our daily top-EPS-revision-performer screen.